Bayer to challenge India cancer drug ruling

An assortment of pills Natco Pharma's version of Nexavar will be much cheaper for patients

Related Stories

German drug maker Bayer has said it will challenge India's decision to allow the production of a cheaper generic copy of a patented cancer drug.

Last year, India allowed Natco Pharma to produce Nexavar and, on Monday, the patent appeals office rejected Bayer's plea to overturn that ruling.

On Tuesday, Bayer said it "strongly" disagreed with the decision and would appeal in the high court of Mumbai.

Bayer sells the drug for 280,000 rupees ($5,118; £3,374) for a 120-tablet pack.

Natco says a 120-tablet pack of Nexavar will be available for 8,800 rupees ($176; £112).

"Bayer is committed to protecting its patents for Nexavar and will rigorously continue to defend our intellectual property rights within the Indian legal system," the company said in a statement quoted by the Associated Press.

Health groups have welcomed the decision, saying it would lead to more affordable versions of patented medicines.

"The decision means that the way has been paved for compulsory licenses to be issued on other drugs, now patented in India and priced out of affordable reach, to be produced by generic companies and sold at a fraction of the price,'' Leena Menghaney of the medical charity Medecins Sans Frontieres (MSF) said.

This is the first case in India of a company being granted a "compulsory license" to manufacture a patented drug. Under the rule, Natco must pay 7% in royalties to Bayer.

More on This Story

Related Stories

More India stories


Features & Analysis

  • Prostitute in red light district in Seoul, South KoreaSex for soldiers

    How Korea helped prostitutes work near US military bases

  • LuckyDumped

    The rubbish collector left on the scrap heap as his city cleans up

  • A woman gets a Thanksgiving meal at a church in FergusonFamily fears

    Three generations in Ferguson share Thanksgiving reflections

  • Canada joins TwitterTweet North

    Canada's self-deprecating social media feed

Elsewhere on the BBC

  • IslandsUnmapped places

    Will the age-old quest to capture uncharted land and space ever end?


  • All-inclusive holidaysThe Travel Show Watch

    With all-inclusive holidays seeing a resurgence are local trades missing out to big resorts?

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.